Pancreatic Cancer Research

ResearcherUniversity College London Hospitals NHS Foundation TrustActive in the last 2 years

Fieke E. M. Froeling

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8653-8164; OpenAlex author ID A5066104383. Sources: OpenAlex.

Their work

Papers
18
Trials
0
Grants
0
Labs led
0
Collaborators
94
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: 2 papers · 2019: none · 2020: 3 papers · 2021: 3 papers · 2022: 1 paper · 2023: none · 2024: none · 2025: 5 papers · 2026: 3 papers

Papers 18

  1. Clonal evolutionary analysis reveals patterns of malignant transformation of Intraductal Papillary Mucinous Neoplasms of the pancreas. Co-author DOI 10.1038/s41467-026-69762-w↗
  2. Clinical and molecular landscape of surgically resected early onset pancreatic cancer. Co-author DOI 10.1093/bjs/znag032↗
  3. Morphospatial profiling of cancer-associated fibroblasts reveals architectural subtypes of pancreatic ductal adenocarcinoma Co-author DOI 10.64898/2026.02.06.704414↗
  4. Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study. Co-author DOI 10.1016/j.ejso.2024.109544↗
  5. Sequential ATR and PARP inhibition overcomes acquired DNA damaging agent resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-025-03051-z↗
  6. Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2. Co-author DOI 10.1186/s12885-024-13333-z↗
  7. PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Panc… Co-author DOI 10.1200/jco-25-00436↗
  8. Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metast… Co-author DOI 10.1200/jco-25-02195↗
  9. Exploring the Biology of Cancer-Associated Fibroblasts in Pancreatic Cancer. Co-author DOI 10.3390/cancers14215302↗
  10. Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Co-author DOI 10.1016/j.annonc.2020.11.013↗
  11. Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis. Co-author DOI 10.1200/jco.20.03238↗
  12. Molecular Subtyping and Precision Medicine for Pancreatic Cancer. Co-author DOI 10.3390/jcm10010149↗
  13. Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. Co-author DOI 10.1038/s41467-020-18636-w↗
  14. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Co-author DOI 10.1038/s41588-019-0566-9↗
  15. Author Correction: Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Co-author DOI 10.1038/s41588-020-0588-3↗
  16. Pancreatic cancer foiled by a switch of tumour subtype. Co-author DOI 10.1038/d41586-018-05129-6↗
  17. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-18-0349↗
  18. Homeostatic restoration of desmoplastic stroma rather than its ablation slows pancreatic cancer progression. Co-author DOI 10.1053/j.gastro.2015.02.043↗

Closest collaborators

The 25 strongest of 94 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David Kuang-Fu Chang · 8 shared papers, 2021–2026 · strength 1.55
  2. Stephan B. Dreyer · 6 shared papers, 2021–2026 · strength 1.30
  3. Andrew Victor Biankin · 5 shared papers, 2021–2026 · strength 0.90
  4. Adam S. Bryce · 3 shared papers, 2022–2026 · strength 0.73
  5. David Arthur Tuveson · 5 shared papers, 2018–2025 · strength 0.64
  6. Antonio Pea · 3 shared papers, 2021–2026 · strength 0.49
  7. Nigel Balfour Jamieson · 2 shared papers, 2026 · strength 0.49
  8. Colin J. McKay · 2 shared papers, 2026 · strength 0.49
  9. Sandra Elisabeth Fischer · 4 shared papers, 2020–2025 · strength 0.47
  10. Robert C. Grant · 4 shared papers, 2020–2025 · strength 0.47
  11. Grainne Mary O'Kane · 4 shared papers, 2020–2025 · strength 0.47
  12. Jennifer Jane Knox · 4 shared papers, 2020–2025 · strength 0.47
  13. Steve Gallinger · 4 shared papers, 2020–2025 · strength 0.47
  14. Daniel John Renouf · 4 shared papers, 2020–2025 · strength 0.47
  15. Faiyaz Notta · 4 shared papers, 2020–2025 · strength 0.47
  16. Raffaella Casolino · 3 shared papers, 2021 · strength 0.40
  17. Hemant Mahendrakumar Kocher · 3 shared papers, 2015–2025 · strength 0.38
  18. Harshabad Singh · 2 shared papers, 2025 · strength 0.33
  19. Craig Devoe · 2 shared papers, 2025 · strength 0.33
  20. Kai Duan · 2 shared papers, 2025 · strength 0.33
  21. Eileen Mary O'Reilly · 2 shared papers, 2025 · strength 0.33
  22. Raymond Jang · 2 shared papers, 2025 · strength 0.33
  23. Daniel A. King · 2 shared papers, 2025 · strength 0.33
  24. Andrew J. Aguirre · 2 shared papers, 2025 · strength 0.33
  25. Elizabeth M. Jaffee · 2 shared papers, 2025 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.